Genetics plays an important role in coronary heart disease (CHD) but the clinical utility of a genomic risk score (GRS) relative to clinical risk scores, such as the Framingham Risk Score (FRS), is unclear.
Introduction
Early and accurate identification of individuals with increased risk of coronary heart disease (CHD) is critical for effective implementation of preventative lifestyle modifications and medical interventions, such as statin treatment 1, 2 . To this end, risk scores such as the Framingham Risk Score (FRS) 3 and the American College of Cardiology / American Heart Association 2013 risk score (ACC/AHA13) 1 , based on clinical factors and lipid measurements, have been developed and are widely used. Although the scores can identify individuals at very high risk, a large proportion of individuals developing CHD during the next 10 years remain unidentified. In particular, they do not provide sufficient discrimination at a younger age when implementation of preventative measures is likely to provide the greatest long-term benefit. Genetic factors have long been recognized to make a substantial contribution to CHD risk 4 . Although a positive family history is an independent risk factor for CHD, it may not completely and solely capture genetic risk. Recently, genome-wide association studies (GWAS) have identified 56 genetic loci associated with CHD at genome-wide significance [5] [6] [7] [8] [9] . Studies of the predictive power of the top single nucleotide polymorphisms (SNPs) at some of these loci either individually or in combination have typically shown small improvements in CHD risk prediction [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , probably because together these variants only explain less than 20% of CHD heritability 8 . As demonstrated recently for other traits such as height and BMI 20, 21 , the majority of unexplained heritability is likely hidden amongst the thousands of SNPs that did not reach genome-wide significance. Indeed, recent advances have shown that genomic prediction models that consider all available genetic variants can efficiently stratify those at increased risk of complex disease 22, 23 . To leverage the maximum amount of information, we examined whether a genomic risk score (GRS) comprising a large number of SNPs, including those with less than genome-wide significance, could produce clinically relevant predictive power for CHD risk.
Methods
A summary of the key methods for the study is given here. Additional details are provided in the Supplementary Appendix.
Study design
This study consisted of two main stages (Supplementary Figure S1) . In stage 1, we utilized the largescale CHD genetic association dataset assembled by the CARDIoGRAMplusC4D consortium 8 (downloaded from http://www.cardiogramplusc4d.org) to construct a GRS. Briefly,
CARDIoGRAMplusC4D tested associations of 79,128 SNPs in 63,746 CHD cases and 130,681 controls, including 6,222 SNPs that had shown nominal association with CHD in a prior GWAS meta-analysis 24 .
We extracted information on all these SNPs together with their associated CARDIoGRAMplusC4D 
Prospective Study cohorts
We utilized two sets of prospective cohorts: (i) FINRISK, consisting of three prospective cohorts from Finland with 10-20 years of follow-up, from collections 1992, 1997, and 2002 (FR92, FR97, and FR02, respectively) 25 , and (ii) the Framingham Heart Study (FHS) [26] [27] [28] 
Statistical analysis
Clinical risk scores were based on the FRS (Adult Treatment Panel III) for CHD and/or MI 3 , and the recent ACC/AHA13 risk score 1 for atherosclerotic cardiovascular disease (ASCVD; see Supplementary Tables S1 and S2 for components and derivation of the scores).
GRSs were generated via thinning the CARDIoGRAMplusC4D SNPs by linkage disequilibrium (LD) thresholds and evaluated using logistic regression and area under receiver-operating characteristic curve (AUC) for each threshold (Supplementary Figure S2) . To avoid overfitting we only used weights (log odds) from the CARDIoGRAMplusC4D stage-2 meta-analysis, which were not based on the WTCCC-CAD or MIGen studies (see Supplementary Methods) . We combined the estimates for WTCCC and MIGen-Harps using fixed-effects inverse-variance weighted meta-analysis. We compared the performance of our GRS with those of Tikkanen et al. 11 and of Mega et al. 30 , which were based on 28 and 27 SNPs associated with CHD at genome-wide significance, respectively. Discrimination of incident CHD events within 10 years was assessed using Harrell's C-index, and the difference in C-index between two models was assessed using the correlated jackknife test. Competing risk analyses were performed using the Aalen-Johansen empirical estimator of cumulative incidence and cause-specific Cox proportional hazard models. Risk reclassification was evaluated using continuous Net
Reclassification Improvement, categorical Net Reclassification Improvement, and Integrated Discrimination Improvement. Meta-analysis of the discrimination statistics was performed using fixedeffect inverse-variance weighting. Additional details on the statistical methods are provided in the Supplementary Methods.
Role of funding source
The sponsors had no role in the conduct or interpretation of the study. The corresponding authors had full access to all data in the study and had final responsibility for the decision to submit for publication.
Results
To construct an optimized GRS using the WTCCC and MIGen-Harps datasets, we first generated a series of GRSs, starting with the 79,128 CARDIoGRAMplusC4D SNPs then progressively lowering the r 2 threshold for LD to reduce the redundancy of predictive information and corresponding number of SNPs in the score (Methods and Supplementary Figure S1 ). An r 2 threshold of 0.7 provided optimal discrimination of CHD cases and controls (WTCCC and MIGen-Harps meta-analysis OR=1.70 per S.D.
of GRS, 95% CI 1.61-1.80; meta-analysis AUC=0.64, 95% CI 0.63-0.66), corresponding to 49,310 SNPs in WTCCC (Supplementary Figure S2 ). Of these 49,310 SNPs, 85.9% (42,364 SNPs) and 95% (46,773 SNPs) were available in the FINRISK and FHS, respectively.
In analyses of incident CHD as a binary outcome in FINRISK, the 49K GRS showed similar odds ratios to WTCCC and MIGen-Harps (OR=1.72, 95% CI 1.59-1.86, per S.D.), but led to higher discrimination than in WTCCC and MIGen-Harps (AUC=0.73, 95% CI 0.71-0.75). In FHS, the association was weaker, OR=1.30 (95% CI 1.19-1.43, per S.D.), with AUC=0.65 (95% CI 0.62-0.67).
Using survival analyses of time to incident CHD, within FINRISK the GRS had stronger association with Figures S3 and S4) . The correlation between GRS and either FRS or ACC/AHA13 scores was close to zero with almost none of the variation in GRS explained by either clinical risk score (in both FINRISK and FHS, r 2 <0.004 between GRS and either FRS and ACC/AHA13; Supplementary Figure S5 ). To further test that the CHD risk conferred by the GRS was largely independent of the effects of cholesterol, we further validated the GRS in the ARGOS familial hypercholesterolemia study, with comparable results to those obtained in WTCCC/MIGen (OR=1.49, 95% CI 1.21-1.84 per S.D. of the GRS, adjusted for sex and 5 principal components) (Supplementary Methods).
To assess the potential clinical utility of the GRS, we compared its performance in discrimination of time to CHD event (C-index) with that of family history, the previously published 28-SNP Tikkanen score 11 the 27-SNP Mega score 30 , and the FRS and ACC/AHA13 clinical risk scores. We also assessed the incremental value of the GRS on top of the clinical risk scores. In both FINRISK and FHS, addition of GRS to either FRS or ACC/AHA13 scores provided statistically significant improvements in C-index, in FINRISK: +1.7% (P<10 -6 ) and +1.6% (P<10 -6 ) for FRS and ACC/AHA13, respectively; in FHS: +1.1% (P<0.0443) and +1.1% (P<0.0344) for FRS and ACC/AHA13, respectively (Figure 1) . Overall, fixedeffects meta-analysis of the two studies showed that GRS improved the C-index by +1.6% (95% CI 0. for ACC/AHA13+GRS over ACC/AHA13 alone (Figure 1) . Larger increases in C-index were observed among older individuals, with the C-index of FRS+GRS compared to FRS alone increasing by 5.1% in individuals aged ≥60 years at baseline, while individuals aged <60 years at baseline showed C-index gains of 1.4% (Supplementary Figure S6) . Within FINRISK, the GRS had higher C-index than family history (+1.9%, P<1.3×10 -6 ). In meta-analysis, the GRS had higher C-index than the published scores of Supplementary Table 3 ).
We next assessed if the GRS improved the individual risk reclassification when added to clinical risk scores. Analyses within FINRISK and FHS are given in Table 2 for FRS and in Supplementary Table   S4 for ACC/AHA13. Overall, meta-analysis of the two datasets showed that the categorical Net Reclassification Improvement (NRI) was 0.1 for both the FRS+GRS and ACC/AHA13+GRS, respectively (P<0.0001; Supplementary Figure S7) . Meta-analysis of continuous NRI was 0.344 (P<0.001) and 0.334 (P<0.001) for the FRS+GRS and ACC/AHA13+GRS, respectively (Supplementary Figure S8) . Meta-analysis of IDI scores showed gains of 0.01 (P<0.001) and 0.009 (P<0.001) for FRS+GRS and ACC/AHA13+GRS, respectively, however IDI scores showed high heterogeneity across FINRISK and FHS (I 2 >97%, P<0.0001, Supplementary Figure S9 ).
The FRS+GRS model also showed consistently higher positive predictive value (PPV) at any given negative predictive value (NPV) for 10-year incident CHD events (Supplementary Figure S10) . For example, in FINRISK, at an NPV of 96% the FRS+GRS achieved a PPV of 40%, compared with a PPV of 23% for FRS alone. In FHS, PPV for FRS+GRS and ACC/AHA13+GRS models was 12-13% at the same NPV, compared with PPV of 10% for the FRS or ACC/AHA13 scores (Supplementary Figure   S10 ).
We next examined how variation in genomic risk translated into differences in cumulative lifetime risk of CHD, using Kaplan-Meier estimates stratified by GRS quintiles for men and women separately ( Figure   2 ). As expected, cumulative risk increased with age for both sexes, with men displaying higher absolute risk than women. In both sexes there were substantial differences in cumulative risk between GRS groups Figure S11) . Similarly, a cause-specific competing-risk Cox analysis of the GRS in FINRISK, adjusting for geographical location and cohort, resulted in a similar hazard ratio as standard Cox analysis (HR=1.70, 95% CI 1.61-1.86).
We next sought to investigate to what degree high genomic risk for CHD could be compensated for by low levels of clinical risk factors at baseline, and vice-versa. When considering baseline smoking status in both FINRISK and FHS, Kaplan-Meier analysis showed a substantial increase in cumulative risk of CHD in men who smoked and also in the top quintile of genomic risk, relative to either non-smokers or smokers at low genomic risk (Figure 3 for FINRISK and Supplementary Figure S12 for FHS). Similar but weaker trends were observed for women in the top versus bottom quintiles of genomic risk. To test whether there was evidence for smoking affecting CHD hazard differently based on an individual's genomic background, we used a Cox model allowing for an interaction term between the GRS and smoking; the interaction was not statistically significant in FINRISK (P=0.91) and FHS (P=0.49).
We also examined the potential compensatory effects of baseline systolic blood pressure and total cholesterol, divided as tertiles of high, medium, and low levels (Supplementary Figures S13 and S14) .
For both systolic blood pressure and total cholesterol, we observed the expected trends in CHD risk for high, medium and low levels. However, males with high versus low levels of systolic blood pressure or total cholesterol showed greater absolute CHD risk if they were in the top versus bottom quintiles of genomic risk.
Notably, in both FINRISK and FHS, women in the bottom quintile of genomic risk showed smaller differences in cumulative CHD risk when stratified by smoking. For tertiles of systolic blood pressure or total cholesterol, low genomic risk women in FINRISK showed similarly small differences in risk, but the effects in FHS for this subgroup were not consistent. Cox models allowing for interactions between the GRS and systolic blood pressure or total cholesterol did not show statistically significant interactions in either FINRISK or FHS (P>0.2 for all).
Discussion
We have generated a GRS for CHD based on 49,310 SNPs and, using three prospective FINRISK and two FHS prospective cohorts, demonstrated that the GRS is associated with incident CHD events independently of established and widely-used clinical risk scores or individual CHD risk factors, including family history. Secondary validation in a familial hypercholesterolemia study (ARGOS) showed that GRS was also associated with CHD in this group of high-risk individuals. Subsequently, combining the GRS with established risk scores improved 10-year CHD risk prediction in FINRISK and FHS. We have also shown that the GRS can be leveraged to achieve meaningful lifetime CHD risk stratification, and that the impact of traditional CHD risk factors such as smoking, blood pressure, and cholesterol, vary substantially depending on the underlying genetic risk, thus offering the potential for both earlier and more targeted preventative efforts.
A distinctive feature of our analysis compared with previous studies 11, 30 examining the predictive utility of GRS for CHD is that the best predictive model was achieved here with SNPs that did not necessarily reach genome-wide or even statistical significance in previous GWA studies. Genome-wide SNP models have been applied successfully to other heritable human traits which seem to follow an "infinitesimal" genetic architecture, such as height 20 . These results highlight the differing goals of GWAS and of genomic prediction: the stringent detection of causal genetic variants involved in the disease process versus the construction of a model that robustly and maximally predicts future disease. While stringent procedures for minimizing the false positive rate of associated loci in GWAS are appropriate, these concerns are less relevant in construction of GRSs, especially when there are a large number of weakly correlated SNPs 22 and when rigorous internal and external validation is performed.
While population stratification is a potential confounder of genomic prediction studies, our use of a large worldwide multi-ethnic meta-analysis to develop the GRS together with two fully independent prospective validation datasets and three independent case/control datasets minimizes this potential. Our GRS was constructed from the CARDIoGRAMplusC4D stage-2 meta-analysis and the FINRISK and FHS individuals are both independent of that study and of broadly European ancestry; thus it is unlikely that the GRS is substantially confounded by fine-scale population structure within these cohorts. Further, the LD-thinning threshold to maximize prediction was determined in the WTCCC and MIGen datasets prior to applying the GRS to ARGOS, FINRISK, or FHS. Nevertheless, for some measures, GRS gains were less pronounced in FHS than in FINRISK. This may partly be due to the different definitions of CHD in these studies or to differences in environmental exposures. In addition, the FRS was developed in the FHS, leading to potential over-estimation of its association with CHD in the current analysis. Hence, there may be benefit from future development of population-specific GRSs, which may yield greater predictive power within each population.
The association of the GRS with incident CHD was not substantially attenuated by traditional risk factors or clinical risk scores derived from these risk factors. Furthermore, the GRS was strongly associated with CHD in a study consisting purely of individuals with familial hypercholesterolemia. These results suggest that genomic risk exerts its effect on CHD risk through molecular pathways that are largely independent of the effects of cholesterol, systolic blood pressure, and smoking. A hitherto unresolved question has been the extent to which a family history would capture any information that may be provided through genetic analysis. Here, we clearly demonstrate the superior performance of direct genetic information over self-reported family history of CHD, which is often incomplete and imprecise in practice and is influenced by family size and competing causes of death.
While we observed improvements in discrimination (C-index) resulting from adding the GRS to the clinical risk scores when considering adults of all ages, the improvements were substantially higher in older individuals (>60 years old). Rather than being driven by age-related differences in the effect of the GRS, these results are likely driven by differences in the clinical risk scores between the younger and older adults. Unlike the GRSs, the clinical risk scores showed substantial differences across ages, driven by temporal changes in the underlying risk factors as well as age itself. Beyond the aims of identifying older adults with high CHD risk, the invariance of genomic risk makes it particularly useful for CHD risk prediction earlier in life, in young adulthood or before, when traditional risk factors are typically not measured and less likely to be informative of risk later in life.
Stratifying individual baseline smoking, systolic blood pressure, and total cholesterol levels measures into genomic risk groups revealed substantial differences in cumulative risk patterns. Importantly, this demonstrates that improved lifestyle may compensate for the innate increased CHD risk captured by the GRS. For men with high genomic risk, modifiable risk factors showed large effects on cumulative CHD risk. For women, the observed impacts of smoking, systolic blood pressure, and total cholesterol were low or not detectable in the low genomic risk group, particularly in FINRISK, however, we could not determine whether this was due to inadequate statistical power or other biological effects and further studies in larger cohorts of women are necessary to determine any clinical implications. While our study demonstrates both the independent and incremental predictive power provided by our GRS, it is important to note that even when combined with such scores, the overall positive predictive 
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